EMA Authorised: Esbriet (Pirfenidone) — H.A.C. Pharma

View source ↗

Summary

Authorised status for Esbriet (pirfenidone) in the EU for idiopathic pulmonary fibrosis and related respiratory conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Lung Diseases
• Respiratory Tract Diseases

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis;Lung Diseases;Respiratory Tract Diseases. MAH: H.A.C. Pharma. Decision date: 09/07/2026